Neurofarmagen® testing and drug side effects: An evaluation of its use among a real-world case series - 13/04/16
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 1 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Résumé |
Introduction |
Various pharmacokinetic and pharmacodynamics features have proven to be involved in the development of drug-induced side effects in psychiatry and thus pharmacogenetic profiling should be considered during drug selection to avoid the onset of side effects.
Aim |
To explore the usefulness of Neurofarmagen® testing in clinical practice by evaluating whether the genetic profile given by the tool could properly explain the onset of side effects during antipsychotic treatment.
Methods |
The pharmacogenetic profile of ten patients having a history of side effect appeared during to specific a psychopharmacologic treatment was determined by Neurofarmagen® testing tool. The relationship between genetic profile and side effects was evaluated and classified.
Results |
Sixty percent of the sample showed a genomic alteration related to a increased likelihood of having any side effects, one half of which presented pharmacokinetic alteration (slow or intermediate phenotype for the implicated cytochrome) whereas the other half had a pharmacodynamic gene variant (related to dopamine or serotonin pathway).
Conclusion |
the Neurofarmagen® testing tool may be useful in the clinical practice in order to avoid drug-induced side effects.
Le texte complet de cet article est disponible en PDF.Plan
Vol 33 - N° S
P. S466 - mars 2016 Retour au numéro
Article précédent
- Differential binding of CREB, USF, and c-Myc to the calreticulin human specific –220C may be linked with the evolution of higher brain functions in human
- S. Farashi
- Psychiatric manifestations of Niemann-Pick type C disease – two case reports
- J. Rebelo, M. Oliveira, P. Nunes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?